Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus

Zaid Al-Nakeeb, Vidmantas Petraitis, Joanne Goodwin, Ruta Petraitiene, Thomas J. Walsh, William W. Hope

Research output: Contribution to journalArticle

Abstract

Amphotericin B is a first-line agent for the treatment of invasive aspergillosis. However, relatively little is known about the pharmacodynamics of amphotericin B for invasive pulmonary aspergillosis. We studied the pharmacokinetics (PK) and pharmacodynamics (PD) of amphotericin B deoxycholate (DAMB), amphotericin B lipid complex (ABLC), and liposomal amphotericin B (LAMB) by using a neutropenic-rabbit model of invasive pulmonary aspergillosis. The study endpoints were lung weight, infarct score, and levels of circulating galactomannan and (1→3)-β-D-glucan. Mathematical models were used to describe PK-PD relationships. The experimental findings were bridged to humans by Monte Carlo simulation. Each amphotericin B formulation induced a dose-dependent decline in study endpoints. Near-maximal antifungal activity was evident with DAMB at 1 mg/kg/day and ABLC and LAMB at 5 mg/kg/day. The bridging study suggested that the "average" patient receiving LAMB at 3 mg/kg/day was predicted to have complete suppression of galactomannan and (1→3)-β-D-glucan levels, but 20 to 30% of the patients still had a galactomannan index of >1 and (1→3)-β-D-glucan levels of >60 pg/ml. All formulations of amphotericin B induce a dose-dependent reduction in markers of lung injury and circulating fungus-related biomarkers. A clinical dosage of liposomal amphotericin B of 3 mg/kg/day is predicted to cause complete suppression of galactomannan and (1→3)-β-D-glucan levels in the majority of patients.

Original languageEnglish (US)
Pages (from-to)2735-2745
Number of pages11
JournalAntimicrobial Agents and Chemotherapy
Volume59
Issue number5
DOIs
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

Aspergillus fumigatus
Amphotericin B
Invasive Pulmonary Aspergillosis
Pharmacokinetics
Aspergillosis
Lung Injury
liposomal amphotericin B
deoxycholate drug combination amphotericin B
Fungi
Theoretical Models
Biomarkers
Rabbits
Weights and Measures
Lung
galactomannan
polyglucosan

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus. / Al-Nakeeb, Zaid; Petraitis, Vidmantas; Goodwin, Joanne; Petraitiene, Ruta; Walsh, Thomas J.; Hope, William W.

In: Antimicrobial Agents and Chemotherapy, Vol. 59, No. 5, 01.05.2015, p. 2735-2745.

Research output: Contribution to journalArticle

Al-Nakeeb, Zaid ; Petraitis, Vidmantas ; Goodwin, Joanne ; Petraitiene, Ruta ; Walsh, Thomas J. ; Hope, William W. / Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus. In: Antimicrobial Agents and Chemotherapy. 2015 ; Vol. 59, No. 5. pp. 2735-2745.
@article{3ab7a5719edf4365a8b5b2ed68481f4e,
title = "Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus",
abstract = "Amphotericin B is a first-line agent for the treatment of invasive aspergillosis. However, relatively little is known about the pharmacodynamics of amphotericin B for invasive pulmonary aspergillosis. We studied the pharmacokinetics (PK) and pharmacodynamics (PD) of amphotericin B deoxycholate (DAMB), amphotericin B lipid complex (ABLC), and liposomal amphotericin B (LAMB) by using a neutropenic-rabbit model of invasive pulmonary aspergillosis. The study endpoints were lung weight, infarct score, and levels of circulating galactomannan and (1→3)-β-D-glucan. Mathematical models were used to describe PK-PD relationships. The experimental findings were bridged to humans by Monte Carlo simulation. Each amphotericin B formulation induced a dose-dependent decline in study endpoints. Near-maximal antifungal activity was evident with DAMB at 1 mg/kg/day and ABLC and LAMB at 5 mg/kg/day. The bridging study suggested that the {"}average{"} patient receiving LAMB at 3 mg/kg/day was predicted to have complete suppression of galactomannan and (1→3)-β-D-glucan levels, but 20 to 30{\%} of the patients still had a galactomannan index of >1 and (1→3)-β-D-glucan levels of >60 pg/ml. All formulations of amphotericin B induce a dose-dependent reduction in markers of lung injury and circulating fungus-related biomarkers. A clinical dosage of liposomal amphotericin B of 3 mg/kg/day is predicted to cause complete suppression of galactomannan and (1→3)-β-D-glucan levels in the majority of patients.",
author = "Zaid Al-Nakeeb and Vidmantas Petraitis and Joanne Goodwin and Ruta Petraitiene and Walsh, {Thomas J.} and Hope, {William W.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1128/AAC.04723-14",
language = "English (US)",
volume = "59",
pages = "2735--2745",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "5",

}

TY - JOUR

T1 - Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus

AU - Al-Nakeeb, Zaid

AU - Petraitis, Vidmantas

AU - Goodwin, Joanne

AU - Petraitiene, Ruta

AU - Walsh, Thomas J.

AU - Hope, William W.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Amphotericin B is a first-line agent for the treatment of invasive aspergillosis. However, relatively little is known about the pharmacodynamics of amphotericin B for invasive pulmonary aspergillosis. We studied the pharmacokinetics (PK) and pharmacodynamics (PD) of amphotericin B deoxycholate (DAMB), amphotericin B lipid complex (ABLC), and liposomal amphotericin B (LAMB) by using a neutropenic-rabbit model of invasive pulmonary aspergillosis. The study endpoints were lung weight, infarct score, and levels of circulating galactomannan and (1→3)-β-D-glucan. Mathematical models were used to describe PK-PD relationships. The experimental findings were bridged to humans by Monte Carlo simulation. Each amphotericin B formulation induced a dose-dependent decline in study endpoints. Near-maximal antifungal activity was evident with DAMB at 1 mg/kg/day and ABLC and LAMB at 5 mg/kg/day. The bridging study suggested that the "average" patient receiving LAMB at 3 mg/kg/day was predicted to have complete suppression of galactomannan and (1→3)-β-D-glucan levels, but 20 to 30% of the patients still had a galactomannan index of >1 and (1→3)-β-D-glucan levels of >60 pg/ml. All formulations of amphotericin B induce a dose-dependent reduction in markers of lung injury and circulating fungus-related biomarkers. A clinical dosage of liposomal amphotericin B of 3 mg/kg/day is predicted to cause complete suppression of galactomannan and (1→3)-β-D-glucan levels in the majority of patients.

AB - Amphotericin B is a first-line agent for the treatment of invasive aspergillosis. However, relatively little is known about the pharmacodynamics of amphotericin B for invasive pulmonary aspergillosis. We studied the pharmacokinetics (PK) and pharmacodynamics (PD) of amphotericin B deoxycholate (DAMB), amphotericin B lipid complex (ABLC), and liposomal amphotericin B (LAMB) by using a neutropenic-rabbit model of invasive pulmonary aspergillosis. The study endpoints were lung weight, infarct score, and levels of circulating galactomannan and (1→3)-β-D-glucan. Mathematical models were used to describe PK-PD relationships. The experimental findings were bridged to humans by Monte Carlo simulation. Each amphotericin B formulation induced a dose-dependent decline in study endpoints. Near-maximal antifungal activity was evident with DAMB at 1 mg/kg/day and ABLC and LAMB at 5 mg/kg/day. The bridging study suggested that the "average" patient receiving LAMB at 3 mg/kg/day was predicted to have complete suppression of galactomannan and (1→3)-β-D-glucan levels, but 20 to 30% of the patients still had a galactomannan index of >1 and (1→3)-β-D-glucan levels of >60 pg/ml. All formulations of amphotericin B induce a dose-dependent reduction in markers of lung injury and circulating fungus-related biomarkers. A clinical dosage of liposomal amphotericin B of 3 mg/kg/day is predicted to cause complete suppression of galactomannan and (1→3)-β-D-glucan levels in the majority of patients.

UR - http://www.scopus.com/inward/record.url?scp=84931287874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931287874&partnerID=8YFLogxK

U2 - 10.1128/AAC.04723-14

DO - 10.1128/AAC.04723-14

M3 - Article

C2 - 25712363

AN - SCOPUS:84931287874

VL - 59

SP - 2735

EP - 2745

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 5

ER -